ASS1 is recognised as the rate-limiting enzyme in arginine synthesis, and in many tumours, including hepatocellular carcinoma, melanoma, prostate cancer, and renal cancer, ASS1 expression is downregulated or even absent, which prevents these tumours from synthesising arginine and thus makes them dependent on exogenous arginine. This evidence concerns the gene ASS1 and prostate cancer.